OBJECTIVE: To assess the relationship between statins and prognosis in ischemic and nonischemic patients with heart failure (HF) in a real-life cohort followed up for a long period. PATIENTS AND METHODS: This prospective study included 960 patients with HF with preserved or depressed left ventricular ejection fraction (LVEF), irrespective of HF etiology, who were referred to the HF clinic of a university hospital between August 1, 2001, and December 31, 2008. The patients were followed up for a maximum of 9.1 years (median, 3.7 years), and survival in ischemic and nonischemic patients was determined. RESULTS: Median age was 69 years, and median LVEF was 31%. Of the 960 patients, 532 (55.4%) had ischemic HF etiology, and most received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (846; 88.1%) and β-blockers (776; 80.8%). Patients with HF of ischemic origin were more often treated with statins (P<.001). During follow-up, 440 patients (45.8%) died. Statin therapy was associated with significantly improved survival (hazard ratio, 0.45 [95% confidence interval, 0.37-0.54]; P<.001). After adjustment for HF prognostic factors (age, sex, cholesterol level, New York Heart Association class, HF etiology, LVEF, body mass index, HF duration, atrial fibrillation, implantable cardioverter-defibrillator therapy, and medicines), statins remained significantly associated with lower mortality risk in both ischemic (P=.007) and nonischemic (P=.002) patients. CONCLUSION: In contrast to results of large randomized trials, statins were independently and significantly associated with lower mortality risk in our real-life HF cohort, including patients with nonischemic HF etiology.
OBJECTIVE: To assess the relationship between statins and prognosis in ischemic and nonischemic patients with heart failure (HF) in a real-life cohort followed up for a long period. PATIENTS AND METHODS: This prospective study included 960 patients with HF with preserved or depressed left ventricular ejection fraction (LVEF), irrespective of HF etiology, who were referred to the HF clinic of a university hospital between August 1, 2001, and December 31, 2008. The patients were followed up for a maximum of 9.1 years (median, 3.7 years), and survival in ischemic and nonischemic patients was determined. RESULTS: Median age was 69 years, and median LVEF was 31%. Of the 960 patients, 532 (55.4%) had ischemic HF etiology, and most received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (846; 88.1%) and β-blockers (776; 80.8%). Patients with HF of ischemic origin were more often treated with statins (P<.001). During follow-up, 440 patients (45.8%) died. Statin therapy was associated with significantly improved survival (hazard ratio, 0.45 [95% confidence interval, 0.37-0.54]; P<.001). After adjustment for HF prognostic factors (age, sex, cholesterol level, New York Heart Association class, HF etiology, LVEF, body mass index, HF duration, atrial fibrillation, implantable cardioverter-defibrillator therapy, and medicines), statins remained significantly associated with lower mortality risk in both ischemic (P=.007) and nonischemic (P=.002) patients. CONCLUSION: In contrast to results of large randomized trials, statins were independently and significantly associated with lower mortality risk in our real-life HF cohort, including patients with nonischemic HF etiology.
Authors: Srikanth Sola; Muhammad Q S Mir; Stamatios Lerakis; Neeraj Tandon; Bobby V Khan Journal: J Am Coll Cardiol Date: 2005-12-20 Impact factor: 24.094
Authors: Kiran K Khush; David D Waters; Vera Bittner; Prakash C Deedwania; John J P Kastelein; Sandra J Lewis; Nanette K Wenger Journal: Circulation Date: 2007-01-29 Impact factor: 29.690
Authors: John Kjekshus; Eduard Apetrei; Vivencio Barrios; Michael Böhm; John G F Cleland; Jan H Cornel; Peter Dunselman; Cândida Fonseca; Assen Goudev; Peer Grande; Lars Gullestad; Ake Hjalmarson; Jaromir Hradec; András Jánosi; Gabriel Kamenský; Michel Komajda; Jerzy Korewicki; Timo Kuusi; François Mach; Vyacheslav Mareev; John J V McMurray; Naresh Ranjith; Maria Schaufelberger; Johan Vanhaecke; Dirk J van Veldhuisen; Finn Waagstein; Hans Wedel; John Wikstrand Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Elisabet Zamora; Carles Díez-López; Josep Lupón; Marta de Antonio; Mar Domingo; Javier Santesmases; María Isabel Troya; Crisanto Díez-Quevedo; Salvador Altimir; Antoni Bayes-Genis Journal: J Am Heart Assoc Date: 2016-03-24 Impact factor: 5.501
Authors: S W Kim; K Y Bae; J M Kim; I S Shin; Y J Hong; Y Ahn; M H Jeong; M Berk; J S Yoon Journal: Transl Psychiatry Date: 2015-08-18 Impact factor: 6.222